[go: up one dir, main page]

MA52593A - 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1 - Google Patents

1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1

Info

Publication number
MA52593A
MA52593A MA052593A MA52593A MA52593A MA 52593 A MA52593 A MA 52593A MA 052593 A MA052593 A MA 052593A MA 52593 A MA52593 A MA 52593A MA 52593 A MA52593 A MA 52593A
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyridines
pde1 inhibitors
pde1
inhibitors
Prior art date
Application number
MA052593A
Other languages
English (en)
Inventor
Carl Martin Sebastian Clementson
Mikkel Jessing
Karsten Juhl
Jan Kehler
Morten Langgård
Mauro Marigo
Lars Kyhn Rasmussen
Paulo Jorge Vieira Vital
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA52593A publication Critical patent/MA52593A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA052593A 2016-07-04 2017-06-30 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1 MA52593A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600397 2016-07-04
DKPA201600612 2016-10-11
DKPA201700236 2017-04-04

Publications (1)

Publication Number Publication Date
MA52593A true MA52593A (fr) 2021-03-17

Family

ID=60806291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052593A MA52593A (fr) 2016-07-04 2017-06-30 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1

Country Status (39)

Country Link
US (7) US10034861B2 (fr)
EP (2) EP3689874A1 (fr)
JP (1) JP7096171B2 (fr)
KR (2) KR102488909B1 (fr)
CN (1) CN109311872B (fr)
AU (1) AU2017291794C1 (fr)
CA (1) CA3026857A1 (fr)
CL (1) CL2019000010A1 (fr)
CO (1) CO2018013803A2 (fr)
CR (1) CR20190003A (fr)
CY (1) CY1122957T1 (fr)
DK (1) DK3478681T3 (fr)
DO (1) DOP2018000266A (fr)
EC (1) ECSP18093944A (fr)
ES (1) ES2784655T3 (fr)
GE (1) GEP20207172B (fr)
HR (1) HRP20200440T1 (fr)
HU (1) HUE048576T2 (fr)
IL (1) IL263511B (fr)
JO (1) JO3819B1 (fr)
LT (1) LT3478681T (fr)
MA (1) MA52593A (fr)
ME (1) ME03672B (fr)
MX (1) MX375782B (fr)
MY (1) MY197140A (fr)
PE (1) PE20190339A1 (fr)
PH (1) PH12018502604A1 (fr)
PL (1) PL3478681T3 (fr)
PT (1) PT3478681T (fr)
RS (1) RS60072B1 (fr)
RU (1) RU2759380C2 (fr)
SG (1) SG11201810965YA (fr)
SI (1) SI3478681T1 (fr)
SM (1) SMT202000148T1 (fr)
SV (1) SV2018005801A (fr)
TW (1) TWI763683B (fr)
UA (1) UA122824C2 (fr)
WO (1) WO2018007249A1 (fr)
ZA (1) ZA201808257B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
HRP20211784T1 (hr) * 2017-12-14 2022-02-18 H. Lundbeck A/S Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US20210205310A1 (en) 2018-05-25 2021-07-08 Intra-Cellular Therapies, Inc. Organic compounds
BR112021015853A2 (pt) 2019-02-13 2021-10-05 Ptc Therapeutics, Inc. Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar
EP3924050A1 (fr) 2019-02-13 2021-12-22 PTC Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
US20220340546A1 (en) * 2019-06-14 2022-10-27 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021253180A1 (fr) * 2020-06-15 2021-12-23 Novartis Ag Méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-4,5,6, 7-tétrahydro-1h-cyclopenta[b]pyridine-3-carboxylate et méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-1,4,5,7-tétrahydrofuro[3,4-b]pyridine-3-carboxylate utilisés en tant qu'activateurs de cav1.2
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RU2348633C2 (ru) * 2002-12-23 2009-03-10 Глаксо Груп Лимитед ПИРАЗОЛО[3,4-b]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
EP1763528B1 (fr) 2004-07-05 2008-11-26 Astellas Pharma Inc. Derives de pyrazolopyridine
KR100710430B1 (ko) * 2004-08-24 2007-04-24 삼성코닝 주식회사 면광원 장치 및 이를 갖는 백 라이트 유닛
ES2326827T3 (es) 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
RU2402549C3 (ru) 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
WO2010065153A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composés organiques
EP2440234A4 (fr) 2009-06-10 2013-11-06 Univ New York Ciblage immunologique de protéines tau pathologiques
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP2699572B1 (fr) 2011-04-21 2016-08-10 Origenis GmbH Composés hétérocycliques en tant qu'inhibiteurs de kinases
CN104024258B (zh) * 2011-09-01 2017-02-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
MX2014011134A (es) 2012-03-19 2014-12-10 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos.
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
WO2015002754A2 (fr) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Nouveaux inhibiteurs de bromodomaines bicycliques
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
WO2015026683A1 (fr) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à répétitions riches en leucine
AP2016009370A0 (en) 2014-02-19 2016-08-31 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
CA2993630A1 (fr) 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines comme inhibiteurs de bace1
WO2017100276A1 (fr) 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et méthodes pour traiter, soulager et prévenir des ulcères de la peau associés au diabète
DE112015007181T5 (de) 2015-12-09 2018-08-23 Ford Global Technologies, Llc Warnung für zurückgelassenes Mobilgerät
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
HRP20211784T1 (hr) 2017-12-14 2022-02-18 H. Lundbeck A/S Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環

Also Published As

Publication number Publication date
AU2017291794A1 (en) 2018-12-20
US20200360343A1 (en) 2020-11-19
EP3478681A1 (fr) 2019-05-08
AU2017291794C1 (en) 2022-01-13
PL3478681T3 (pl) 2020-06-15
SG11201810965YA (en) 2019-01-30
KR102576888B1 (ko) 2023-09-08
LT3478681T (lt) 2020-04-10
KR20190025606A (ko) 2019-03-11
PH12018502604A1 (en) 2019-10-21
SI3478681T1 (sl) 2020-04-30
US20210023056A1 (en) 2021-01-28
IL263511B (en) 2020-11-30
CY1122957T1 (el) 2021-10-29
TW201806950A (zh) 2018-03-01
EP3478681B1 (fr) 2020-02-26
CR20190003A (es) 2019-05-06
RU2018143324A3 (fr) 2020-08-12
MX375782B (es) 2025-03-07
AU2017291794B2 (en) 2021-07-22
US20180000786A1 (en) 2018-01-04
ES2784655T3 (es) 2020-09-29
SMT202000148T1 (it) 2020-05-08
US20200129480A1 (en) 2020-04-30
CL2019000010A1 (es) 2019-02-22
DK3478681T3 (da) 2020-03-23
KR20220154262A (ko) 2022-11-21
CA3026857A1 (fr) 2018-01-11
DOP2018000266A (es) 2019-03-15
SV2018005801A (es) 2019-02-13
GEP20207172B (en) 2020-10-26
PE20190339A1 (es) 2019-03-07
ME03672B (fr) 2020-10-20
RS60072B1 (sr) 2020-05-29
HUE048576T2 (hu) 2020-08-28
ZA201808257B (en) 2020-05-27
US10034861B2 (en) 2018-07-31
US10806718B2 (en) 2020-10-20
PT3478681T (pt) 2020-04-03
MY197140A (en) 2023-05-26
CO2018013803A2 (es) 2019-01-18
IL263511A (en) 2019-01-31
ECSP18093944A (es) 2019-01-31
US11491140B2 (en) 2022-11-08
JP7096171B2 (ja) 2022-07-05
RU2759380C2 (ru) 2021-11-12
UA122824C2 (uk) 2021-01-06
RU2018143324A (ru) 2020-08-04
JO3819B1 (ar) 2021-01-31
US11026924B2 (en) 2021-06-08
JOP20180116A1 (ar) 2019-01-30
US20190105302A1 (en) 2019-04-11
MX2018015734A (es) 2019-03-21
HRP20200440T1 (hr) 2020-06-12
KR102488909B1 (ko) 2023-01-13
US20210015794A1 (en) 2021-01-21
US20200375950A1 (en) 2020-12-03
CN109311872B (zh) 2021-08-20
EP3689874A1 (fr) 2020-08-05
JP2019524689A (ja) 2019-09-05
US10512632B2 (en) 2019-12-24
WO2018007249A1 (fr) 2018-01-11
CN109311872A (zh) 2019-02-05
TWI763683B (zh) 2022-05-11
US11026923B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
FR22C1058I1 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
DK3558990T3 (da) Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
HUE048395T2 (hu) Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára
IL252065B (en) Thiano[2,3-c]pyrrol-4-ion derivatives as erk inhibitors
KR102161364B9 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
EP3452481A4 (fr) Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
EP3280715A4 (fr) Nouvelles imidazo[1,5-a]pyridines substituées en 5ème ou 8ème position en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
DK3371185T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
DK3712152T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
LT3442975T (lt) 1,5-dihidro-4h-pirazol[3,4-d]pirimidin-4-onai ir 1,5-dihidro-4h-pirazol[4,3-c]piridin-4-onai kaip pde1 inhibitoriai
EP3487851A4 (fr) Dérivés de l'aminopyridine et leur utilisation en tant qu'inhibiteurs sélectifs d'alk-2
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP2922543A4 (fr) Dérivés de pyridone substitués utilisés en tant qu'inhibiteurs de pde10
LT3230289T (lt) 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
HUE057202T2 (hu) Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
DK3356329T3 (da) Fremgangsmåde til fremstilling af 1-(4-methansulfonyl-2-trifluormethylbenzyl)-2-methyl-1H-pyrrolo[2,3-B]pyridin-3-yleddikesyre
MA42604A (fr) 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1
MA46557A (fr) Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
MA47070A (fr) Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisés en tant qu'inhibiteurs de pde1